z-logo
open-access-imgOpen Access
Negative Regulation of Bone Formation by the Transmembrane Wnt Antagonist Kremen-2
Author(s) -
Jochen Schulze,
Sebastian Seitz,
Hiroaki Saito,
Michael Schneebauer,
Robert Percy Marshall,
Anke Baranowsky,
Björn Busse,
Arndt F. Schilling,
Felix W. Friedrich,
Joachim Albers,
Alexander S. Spiro,
Jozef Zustin,
Thomas Streichert,
Kristina Ellwanger,
Christof Niehrs,
Michael Amling,
Roland Baron,
Thorsten Schinke
Publication year - 2010
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0010309
Subject(s) - wnt signaling pathway , osteoclast , osteoblast , lrp5 , bone resorption , dkk1 , osteoprotegerin , microbiology and biotechnology , endocrinology , lrp6 , bone remodeling , medicine , osteoporosis , chemistry , signal transduction , biology , receptor , activator (genetics) , in vitro , biochemistry
Wnt signalling is a key pathway controlling bone formation in mice and humans. One of the regulators of this pathway is Dkk1, which antagonizes Wnt signalling through the formation of a ternary complex with the transmembrane receptors Krm1/2 and Lrp5/6, thereby blocking the induction of Wnt signalling by the latter ones. Here we show that Kremen-2 ( Krm2 ) is predominantly expressed in bone, and that its osteoblast-specific over-expression in transgenic mice ( Col1a1-Krm2 ) results in severe osteoporosis. Histomorphometric analysis revealed that osteoblast maturation and bone formation are disturbed in Col1a1-Krm2 mice, whereas bone resorption is increased. In line with these findings, primary osteoblasts derived from Col1a1-Krm2 mice display a cell-autonomous differentiation defect, impaired canonical Wnt signalling and decreased production of the osteoclast inhibitory factor Opg. To determine whether the observed effects of Krm2 on bone remodeling are physiologically relevant, we analyzed the skeletal phenotype of 24 weeks old Krm2 -deficient mice and observed high bone mass caused by a more than three-fold increase in bone formation. Taken together, these data identify Krm2 as a regulator of bone remodeling and raise the possibility that antagonizing KRM2 might prove beneficial in patients with bone loss disorders.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom